Stay updated with breaking news from Biomedical Technology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In addition to AD, brepocitinib, a topical TYK2/JAK1 inhibitor, is being developed as a treatment for dermatomyositis, SLE, hidradenitis suppurativa, and non-infectious uveitis.
CAMBRIDGE, Mass., Nov. 29, 2022, which recognizes novel technologies that have improved human health. Each year, the prize will celebrate a novel technology and recognize up to four key individuals
Nominations Open for the Merkin Prize in Biomedical Technology GlobeNewswire November 29, 2022 CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Nominations are now open for the first award of the Richard N. Merkin Prize in Biomedical Technology, which recognizes novel technologies that have improved human health. Each year, the prize will...
Merkin Prize Logo The Richard N. Merkin Prize in Biomedical Technology is accepting nominations until Jan. 30, 2023. CAMBRIDGE, Mass. - November 29, 2022 - (Newswire.com) Nominations ar...
Teclistamab (Tecvayli) has been approved for relapsed/refractory multiple myeloma patients who have received at least four lines of therapy; typically, such patients have just a few weeks to live.